Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomized, Phase 2, Umbrella Study to Investigate the Biological Rational of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy

NCT04586244 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04586244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04586244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomized, Phase 2, Umbrella Study to Investigate the Biological Rational of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Terminated
Start date
January 14, 2022
Completion date
January 29, 2024
Enrollment
30 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma